Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Esperion Therapeutics spotlights 2026 ACC AHA multisociety guideline for dyslipidemia management
Esperion Therapeutics has drawn attention to the new 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia, with discussion from cardiovascular medicine figures Dr. Steve Nissen and Dr. C. Michael Gibson. These guidelines are anticipated to significantly impact future cholesterol and cardiovascular risk management. The company, recently ranked 88th on the Financial Times Americas Fastest Growing Companies 2026 list, has also highlighted key data from its NEXLETOL CLEAR Outcomes study, maintaining its prominence in the cardiovascular field.